Real-time prescription monitoring — SafeScript, QScript, ScriptCheckSA

What real-time prescription monitoring is, and why it exists

Real-time prescription monitoring (RTPM) is Australia’s national framework for giving GPs and pharmacists a live view of a patient’s recent prescribing and dispensing history for Schedule 8 and high-risk Schedule 4 medicines. The system runs on the federal PRoDUR backbone (Australian Digital Health Agency — RTPM overview) but each state and territory operates its own branded portal: SafeScript in Victoria, QScript in Queensland, ScriptCheckSA in South Australia, SafeScript NSW, ScriptCheckWA, NTScript, TasScript, and the ACT system.

The reason for its existence is stark. The Penington Institute’s 2024 Annual Overdose Report recorded 2,356 drug-induced deaths in Australia in 2022 — approximately six lives lost every day — with roughly 80 per cent unintentional. In Victoria alone, 547 people died from overdose in 2023, the second-highest figure on record. The top contributing drugs were diazepam, heroin, methamphetamine, alcohol, and pregabalin. The Victorian Department of Health has responded by making SafeScript checks mandatory for every monitored-medicine prescription and by referring 10–30 GPs per month to AHPRA for non-compliance.

For any GP prescribing opioids, benzodiazepines, gabapentinoids, or Z-drugs, RTPM is both a patient-safety tool and a medico-legal obligation. Understanding what the system shows, how to respond to each alert level, and what to document is now a core general practice competency.

A. Core clinical — the AU general-practice framework

Which states have mandatory checks

The RACGP Prescribing drugs of dependence guidelines and each state’s legislative framework define the mandatory-check landscape:

• Victoria — SafeScript mandatory since 1 April 2020 under the Drugs, Poisons and Controlled Substances Act 1981.
• Queensland — QScript mandatory since 1 October 2021, regulations updated 1 July 2024, under the Medicines and Poisons Act 2019.
• South Australia — ScriptCheckSA mandatory since 18 July 2024 under the Controlled Substances Act 1984 amendments, with an exemption for persons over 70 years (excluding dextromoramide and pethidine) and for patients with a life expectancy under 12 months.
• NSW, WA, NT, Tasmania, ACT — systems are operational and strongly encouraged, but the check is not yet a statutory requirement in these jurisdictions.

GPs practising near state borders need to know the rules for both sides: a Victorian GP visiting a patient interstate is subject to Queensland or SA law when prescribing there.

Which medicines are monitored

The core list across all jurisdictions includes all Schedule 8 opioids (morphine, oxycodone, fentanyl, hydromorphone, methadone, buprenorphine including buprenorphine-naloxone for opioid agonist treatment, pethidine, tapentadol), Schedule 8 stimulants (dexamphetamine, lisdexamfetamine, methylphenidate), benzodiazepines (alprazolam — rescheduled to S8 nationally in 2014 — diazepam, temazepam, oxazepam, lorazepam, clonazepam, nitrazepam, midazolam), Z-drugs (zolpidem, zopiclone), codeine combinations (all now S4 after the 2018 TGA reschedule), tramadol, and gabapentinoids (pregabalin and gabapentin). Victoria’s SafeScript also monitors quetiapine given its documented misuse for sedation.

The Victorian Department of Health evidence review (2021) found that gabapentinoids and tramadol warranted inclusion after pregabalin was implicated in 69 deaths in 2020.

The seven-step workflow

The RACGP Part A framework and the Australian Commission on Safety and Quality in Health Care RTPM guidance support the following workflow for any monitored-medicine consultation:

1. Run the RTPM check — in mandated states, before every script; in non-mandated states, at a minimum for all new patients requesting a monitored medicine, anyone with drug-seeking flags, and any polypharmacy scenario combining opioids with benzodiazepines, gabapentinoids, or Z-drugs.
2. Interpret the alert — green (no threshold met), amber (caution — multiple prescribers or dispensers, prior high-dose episode), or red (high-dose opioid, concurrent opioid-benzodiazepine, recent overdose, dependence pattern). The permit flag indicates an active Schedule 8 treatment permit from state health.
3. Clinical assessment — pain severity, functional impact, mood screen (PHQ-9, GAD-7), substance-use screen (AUDIT-C or single-question screen), observed sedation and respiratory rate, injection-site inspection where relevant.
4. Discuss openly with the patient — non-judgmental language is important; the eTG Addiction Medicine module emphasises a person-centred approach that acknowledges the system check as routine safety, not interrogation.
5. Make a clinical decision — proceed, modify, defer, or decline. If tapering is indicated, planned gradual reduction (≤10% of current morphine-equivalent daily dose per fortnight) is the evidence-aligned approach.
6. Document every element — see the template in Section D.
7. Safety-net — offer naloxone, provide overdose-recognition education, discuss driving restrictions under the Austroads AFTD framework, and arrange follow-up within two weeks for any amber or red alert.

B. Evidence: does RTPM reduce opioid-related harm?

What the research shows

Multiple US state-level evaluations and Australian pre-post studies associate prescription drug monitoring programme (PDMP) access — the US equivalent of RTPM — with reductions in opioid prescribing rates, doctor-shopping behaviour, and opioid-related emergency department presentations. A 2019 systematic review (Rhodes et al, PMC) found consistent population-level reductions in prescribed-opioid deaths and doctor-shopping across mandatory-access PDMP states.

In Victoria, SafeScript checks increased substantially after the mandatory legislation took effect, and coroner findings from 2020 onward have documented specific cases where a SafeScript check would have revealed the risk before a fatal prescription was written. The 2026 Lilydale coronial finding and earlier Victorian findings have named GPs by name where failure to check contributed to patient deaths.

The limits of the system

RTPM captures only prescribed and dispensed medicines in the Australian pharmaceutical chain. It does not capture illicit drug use, private compounding outside the PBS or Schedule 8 chain, or medicines obtained overseas. The Victorian 2023 overdose data showing 547 deaths despite mandatory SafeScript since 2020 reflects that illicit supply — particularly novel benzodiazepines (etizolam, flualprazolam, bromazolam, clobromazolam) and nitazenes — is driving a growing share of overdose deaths that RTPM cannot address alone.

A green alert is not a clinical clearance. The RACGP Part C1 opioids guideline is explicit: clinical assessment, functional screening, and substance-use screening are required at every consultation regardless of the system result.

The Ong AHPRA tribunal (2024) — key lessons

The AHPRA Tribunal summary for Dr Beng Ong (July 2024) is the clearest recent statement on what RTPM non-compliance means for registration. Dr Ong prescribed opiates and benzodiazepines to six patients without clinical justification, and for drugs requiring a Department of Health treatment permit, either held no permit or prescribed in excess of the permitted dose. The Victorian Civil and Administrative Tribunal found professional misconduct and cancelled registration with a four-year prohibition on reapplying. The lessons are direct: the S8 permit framework is statutory and lack of a permit is itself misconduct; SafeScript non-compliance compounds the failure; and when the system would have shown the risk and the prescriber did not look, that is documented inaction.

C. The STOP-and-CALL workflow for red alerts

When RTPM returns a red alert — high-dose opioid, concurrent opioid and benzodiazepine, recent overdose, dependence pattern — the recommended response from the RACGP Drugs of Dependence guidelines is systematic:

Stop — do not issue the script today.

Talk — have a non-judgmental conversation with the patient about what the system is showing and invite their explanation.

Options — explore alternatives: non-opioid analgesia, a planned taper, addiction medicine referral, a Mental Health Care Plan, supervised dispensing, or a single-prescriber agreement.

Permit — check whether an S8 treatment permit is required and has been applied for. In Victoria, prescribing Schedule 8 medicines to a drug-dependent person requires a permit before any script; for non-dependent patients the threshold is eight weeks for some categories or 12 weeks for others (SafeScript Vic — Schedule 8 permits and notifications).

Call — your MDO advice line before deviating from a clear red alert. Avant’s medical defence line is 1800 128 268, MDA National is 1800 011 255, and MIPS is 1800 061 113. Drug and Alcohol specialist advice is available through DACAS (Victoria 1800 812 804, NSW 1800 023 687, Queensland 1800 290 928).

Assess — full risk assessment including overdose risk, suicidality, withdrawal signs if relevant, and functional capacity.

Letters and log — write to other prescribers identified in the RTPM and enter a full documentation note as outlined in Section D.

D. Australian operations

MBS items for RTPM-related consultations

Standard consultation items (23 Level B, 36 Level C, 44 Level D) cover the RTPM-triggered consultation — the system check is folded into the consultation time. Red-alert consultations typically attract Level C or D given the assessment, counselling, and documentation required. A Mental Health Care Plan (MBS 2700/2715) is appropriate when chronic-pain prescribing is intertwined with depression, anxiety, PTSD, or substance-use disorder. The GP Chronic Condition Management Plan (MBS 965/967) applies to chronic non-cancer pain co-managed with allied health under the post-July 2025 reform.

The coroner-protective documentation template

The following can be adapted as a clinical software template:

RTPM checked [SafeScript / QScript / ScriptCheckSA] at [date/time]. Result: [colour — e.g. “Amber — 2 prescribers in 90 days; 1 dispenser; total estimated oMEDD approx 60 mg”].

Clinical assessment: pain severity [N/10], function [summary], PHQ-9 [score], AUDIT-C [score], sedation [absent or detail], signs of intoxication [absent or detail].

Patient discussion: [verbatim summary — particularly addressing any amber or red finding].

Plan: [decision and reasoning — e.g. “Continued at current dose; agreed taper 10% per fortnight to target 40 mg oMEDD; single nominated pharmacy; 2-week review booked; declined to add benzodiazepine for sleep — CBT-I referral placed”]

Safety-net: naloxone offered [accepted / declined]; overdose recognition education given; drive restriction under Austroads AFTD discussed; written information provided.

MDO contact: [if applicable — advice line reference number and advice received].

Next review: [date].

PBS considerations for monitored medicines

Schedule 8 opioids require authority for ongoing use in chronic pain; short-course acute severe pain may proceed on streamlined authority with documented duration limits. Buprenorphine-naloxone and methadone for opioid agonist treatment are Section 100 (Highly Specialised Drugs) with state DH permit required. Pregabalin requires authority for chronic neuropathic pain and is not PBS-listed for non-neuropathic pain. Naloxone (Prenoxad nasal spray, Nyxoid) is available free through the Take Home Naloxone Program — offer to anyone prescribed regular opioids and to their family or carers.

E. Special populations

Older adults. Falls, fractures, cognitive impairment, and respiratory depression risk are substantially amplified in people over 65 prescribed opioids or benzodiazepines. The eTG Analgesic module recommends starting at half the standard adult dose, reassessing at every script, and pursuing non-pharmacological analgesia as the primary framework. Melatonin prolonged-release is preferred over Z-drugs or benzodiazepines for sleep in this group. South Australia’s RTPM regulations include an explicit exemption for persons over 70 for certain medicines, acknowledging the palliative and age-related complexity.

Palliative care and cancer pain. Patients on opioids for cancer pain or palliative care are not exempted from RTPM checks in most jurisdictions, but the clinical context is different — total oMEDD ceilings do not apply, and prescribing above standard thresholds is appropriate and documented. The system will show high doses; the documentation explaining palliative intent is the protection. Victoria’s legislative exemptions for acute hospital inpatients and residential aged care residents on continuous therapy reduce the administrative burden in those settings.

Indigenous Australians. The Penington Institute data shows a drug-induced death rate of 23.3 per 100,000 for Indigenous Australians compared with 6.1 per 100,000 for non-Indigenous Australians — a 3.8-fold disparity. MBS item 715 (Aboriginal and Torres Strait Islander Health Assessment) provides a comprehensive review framework that encompasses medication safety, substance-use screening, and harm reduction alongside RTPM. Cultural safety training and community-controlled health organisations are core to equitable RTPM implementation.

Patients near state borders. The legal obligation follows the jurisdiction in which the script is written, not the jurisdiction in which the GP is registered. A GP from Victoria seeing a patient in NSW is subject to NSW rules (non-mandatory but strongly encouraged). Conversely, a NSW GP doing a locum shift in Victoria is subject to the mandatory Victorian check. Practices near borders should have both systems registered and accessible.

When to escalate

The RACGP Drugs of Dependence Part A and the Drug and Alcohol Clinical Advisory Service (DACAS) framework identify clear escalation thresholds:

Referral to addiction medicine or a drug and alcohol specialist is appropriate when there is suspected dependence, an opioid agonist treatment indication, two or more failed taper attempts, pregnancy with opioid or benzodiazepine dependence, complex polypharmacy that cannot be stabilised in general practice, or a red RTPM pattern that persists despite intervention.

Referral to pain medicine is appropriate for chronic non-cancer pain that has not responded to multimodal management after three to six months, for supervision of complex opioid tapers, or for neuropathic pain refractory to first-line agents.

Psychiatry input is appropriate when there is significant comorbid mental illness, suicidality with substance use, or complex PTSD with dependence.

When referring, include the relevant RTPM summary, the assessment details, the previous management history, and the urgency indicator. Contacting the DACAS advice line before the referral is often the fastest way to navigate the local pathway.

What this article is and is not

This article draws on the RACGP Prescribing Drugs of Dependence guidelines (Parts A, B, C1), Therapeutic Guidelines (eTG) Analgesic and Addiction Medicine modules, Australian Medicines Handbook, the Australian Commission on Safety and Quality in Health Care RTPM resources, and each state’s statutory portal documentation. It reflects the regulatory framework as at October 2026 and is intended as a practical orientation for Australian general practitioners and registrars.

It is not personal legal advice, not a substitute for your MDO’s guidance in a specific situation, and not a comprehensive summary of any state’s legislation. The legislative requirements change as states update regulations; always verify current obligations with your state health department and your medical defence organisation before a complex prescribing decision.

For patient-facing information: HealthDirect, SafeScript Victoria patient information, and QScript consumer page.

---

Sources cited

1. RACGP — Prescribing drugs of dependence (Parts A, B, C1)
2. Therapeutic Guidelines (eTG) — Analgesic + Addiction Medicine
3. Australian Medicines Handbook
4. Australian Commission on Safety and Quality in Health Care — RTPM
5. Australian Digital Health Agency — RTPM overview
6. SafeScript Victoria
7. QScript — Queensland Health
8. ScriptCheckSA — SA Health
9. SafeScript NSW
10. ScriptCheckWA — HealthyWA
11. Penington Institute — Annual Overdose Report 2024
12. Coroners Court of Victoria — 547 Victorians overdose deaths 2023
13. Vic DH — Gabapentinoids and tramadol evidence review (2021)
14. AHPRA — Tribunal summary Dr Beng Ong (July 2024)
15. SafeScript Vic — Schedule 8 permits and notifications
16. TGA — Codeine rescheduling final decision 2017
17. Take Home Naloxone Program — health.gov.au
18. DACAS — Drug and Alcohol Clinical Advisory Service
19. Rhodes W et al — Systematic review of PDMP effectiveness (PMC 2019)
20. HealthDirect